In vitro experiments have highlighted that CD83 expression can be restored, with the hope of developing cancer vaccines capable of pharmacologically reactivating DCs/LCs and, consequentially, T cells, restoring antitumor immunity [13,21]. The gene discussed is CD83; the disease is cancer.